The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://lucykvrx999189.wssblogs.com/38952152/glp-3-retatrutide-a-comparative-analysis